Logo

Becton Dickinson: John DeFord, Patrick Kaltenbach, Dave Hickey

Oct 23, 2020

Becton Dickinson announced the retirement of Chief Technology Officer John DeFord, who joined BD with the acquisition of CR Bard in 2017. DeFord will be succeeded by Patrick Kaltenbach, who will serve as CTO and executive vice president. Kaltenbach joined BD as president of the life sciences segment in May 2018 after having most recently served as Agilent's senior vice president and president of that firm's life sciences and applied markets group. Dave Hickey, who currently serves as BD's worldwide president of integrated diagnostics solutions, will be promoted to the position of executive vice president and president of life sciences. The new appointments will be effective Jan. 1, 2021.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.